Danish Biotech Targeting Ion Channels Completes Private Placement

The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M.

Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility to execute its business plan, which includes listing in the Nasdaq Stockholm this year.

Based in Copenhagen, the company develops small molecules that target ion channels. Its pipeline includes a wide range of conditions, such as obesity, type 2 diabetes, cocaine addiction, Parkinson’s, and schizophrenia, the latter being researched in collaboration with Boehringer Ingelheim.

Cover image via TJmedia /Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.